Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-16T05:25:48.276Z Has data issue: false hasContentIssue false
  • English
  • Français

EPA-0809 - Aripiprazole Once-Monthly for the Treatment of Schizophrenia in Obese and Non-Obese Patients; a Post-Hoc Analysis

Published online by Cambridge University Press:  15 April 2020

M. De Hert ,
A. Eramo ,
W. Landsberg ,
L.F. Tsai ,
D. Kostic  and
R. Baker
M. De Hert
Affiliation:
University Psychiatric Centre, Catholic University Leuven Campus Kortenberg, Kortenberg, Belgium
A. Eramo
Affiliation:
Medical Affairs & Phase IV Clinical Affairs, H. Lundbeck A/S, Deerfield, USA
W. Landsberg
Affiliation:
Medical, Otsuka Pharmaceutical Europe, Middlesex, United Kingdom
L.F. Tsai
Affiliation:
Biostatics, Otsuka Pharmaceutical Development and Commercialization Inc., Rockville, USA
D. Kostic
Affiliation:
Global Medical Affairs, Otsuka Pharmaceutical Development and Commercialization Inc., Princeton, USA
R. Baker
Affiliation:
CNS Global Medical Affairs, Otsuka Pharmaceutical Development and Commercialization Inc., Princeton, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

To evaluate efficacy and safety of aripiprazole once-monthly 400mg (AOM-400mg), an extended release injectable suspension of aripiprazole, in obese (BMI =30kg/m2) and non-obese (BMI <30kg/m2) patients with schizophrenia.

Methods:

Data from a 38-week, double-blind, active-controlled, non-inferiority study (NCT00706654); randomisation (2:2:1) to AOM-400mg, oral aripiprazole (10-30mg/day) (ARI), or aripiprazole once-monthly 50mg (AOM-50mg) assessing the efficacy and safety of AOM in patients requiring chronic antipsychotic treatment were used for this post-hoc analysis. We report the overall relapse rates in the 38-week randomized phase. Comparisons of overall relapse rates were analyzed using the Chi-squared test.

Results:

662 patients were randomized to: AOM-400mg (n=265); ARI (n=266); or AOM-50mg (n=131). Of these, the following were obese: AOM- 400mg: n=95; ARI: n=95; AOM-50mg: n=43. In the obese patients, the overall relapse rate was significantly (p=0.0012) lower with AOM-400mg (7.4%) than with AOM-50mg (27.9%). The difference between AOM-400mg and ARI (8.4%) was not significantly different. In the non-obese patients, the overall relapse was significantly (p=0.0153) lower with AOM-400mg (8.8%) than with AOM-50mg (19.3%). The difference between AOM-400mg and ARI (7.6%) was not significantly different. For patients treated with AOM-400mg, the most common TEAEs (>10% in any group) are presented in Table 1.

Table 1.

TEAE: AOM-400mgObeseNon-obese
Insomnia12.6%11.2%
Headache12.6%8.2%
Injection site pain11.6%5.3%
Akathesia10.5%10.6%
Upper respiriatory tract infection10.5%<5%
Weight increase10.5%8.2%
Weight decrease6.3%11.8%

Conclusions:

The efficacy and tolerability of aripiprazole once-monthly 400mg were similar in both the obese and non-obese subgroups.

Disclosure:

Supported by Otsuka Pharmaceutical Development & Commercialization, Inc., and H. Lundbeck A/S

Type
EPW16 - Schizophrenia 2
Information
European Psychiatry , Volume 29 , Issue S1: Abstracts of the 22nd European Congress of Psychiatry , 2014 , pp. 1
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.